Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors

NCT02689336 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Could not recruit any participants

Conditions

Glioma
Rhabdomyosarcoma
Osteosarcoma
Medulloblastoma
Neuroectodermal Tumor
Ependymoma
Ewing's Sarcoma
Wilms Tumor

Interventions

BIOLOGICAL: Erlotinib
DRUG: Temozolomide

Sponsor

Washington University School of Medicine